natgillin/translations-raw huggingface dataset:
I alt 836 patienter fra seks kliniske studier er på forskellige tidspunkter testet for anti-terapeutisk antistofrespons (ATA-respons) på trastuzumabemtansin.
A total of 836 patients from six clinical studies were tested at multiple time points for anti-therapeutic antibody (ATA) responses to trastuzumab emtansine.
I alt 85 patienter (15,2 %), der startede behandlingen med ≤ 500 mg (n=558), fik øget dosis til 600 mg bosutinib.
A total of 85 patients (15.2%) who started treatment at </= 500 mg (n= 558) received dose escalations to 600 mg of bosutinib.
I alt 87 fuldstændige og partielle responser blev observeret, heraf 13, som optrådte mellem 5. og 6. serie, og 3, som optrådte derefter.
Altogether, 87 complete and partial responses were observed, with 13 of these occurring during cycles 5 and 6 and 3 occurring thereafter.
I alt 870 patienter med Ph+ leukæmi blev behandlet med mindst 1 dosis bosutinib som enkeltstof- behandling.
A total of 870 Ph+ leukaemia patients received at least 1 dose of single-agent bosutinib.
I alt 907 patienter (62,3 %) gennemførte forlængelsesfasen med flere cyklusser op til maks. otte behandlingscyklusser.
A total of 907 patients (62.3%) completed the multiple-cycle extension up to a maximum of eight treatment cycles.
I alt blev 104 patienter randomiseret til behandling i dette studie; 53 til Avastin 10 mg/kg hver 2. uge plus placebo og 51 til Avastin 10 mg/kg hver 2. uge plus erlotinib 150 mg dagligt.
A total of 104 patients were randomised to treatment in this trial, 53 to Avastin 10 mg/kg every 2 weeks plus placebo and 51 to Avastin 10 mg/kg every 2 weeks plus erlotinib 150 mg daily.
I alt blev 19 forsøgspersoner, heraf 11 fra baseline-aldersgruppen 4 til 12 år og 8 fra baseline- aldersgruppen 13 til 17 år behandlet i 6 år eller mere.
Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to 17 years were treated 6 years or longer.
I alt blev 19 forsøgspersoner, heraf 11 fra baseline-aldersgruppen 4 til 12 år og 8 fra baseline- aldersgruppen 13 til 17 år, behandlet i 6 år eller mere.
Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to 17 years were treated 6 years or longer.
I alt blev 19 forsøgspersoner, hvoraf 11 fra baseline-aldersgruppen 4 til 12 år og 8 fra baseline-aldersgruppen 13 til 17 år, behandlet i 6 år eller mere.
Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to 17 years were treated 6 years or longer.
I alt blev 199 patienter med GIST randomiseret i forholdet 2:1 til enten 160 mg regorafenib plus bedste understøttende behandling (BSC, N=133) oralt én gang dagligt eller matchende placebo plus BSC (N=66) i 3 uger, efterfulgt af 1 uge uden behandling.
In total, 199 patients with GIST were randomized 2:1 to receive either 160 mg regorafenib plus Best Supportive Care (BSC; N=133) orally once daily or matching placebo plus BSC (N=66) for 3 weeks on therapy followed by 1 week off therapy.
I alt blev 2.076 patienter evalueret (692 patienter på 150 mg, 690 patienter på 300 mg og 694 patienter på placebo).
In total, 2,076 patients were evaluated (692 patients on 150 mg, 690 patients on 300 mg and 694 patients on placebo).
I alt blev 2.114 patienter behandlet i det aktivt-kontrollerede DVT/LE-forebyggelsesstudie RE-MEDY og det placebo-kontrollerede DVT/LE-forebyggelsesstudie RE-SONATE.
A total of 2,114 patients were treated in the active controlled DVT/PE prevention trial, RE-MEDY, and in the placebo-controlled DVT/PE prevention trial, RE-SONATE.
I alt blev 385 forsøgspersoner eksponeret for mere end 14.500 infusioner af Cinryze i disse undersøgelser.
There were a total of 385 subject exposures involving over 14,500 infusions of Cinryze in these studies.
I alt blev 389 patienter behandlet i undersøgelsen, 256 patienter fik daptomycin, og 133 patienter fik standardbehandling.
A total of 389 subjects were treated in the study, including 256 subjects who received daptomycin and 133 subjects who received standard-of-care.
I alt blev 40 tilfælde ekskluderet fra analysen, da disse kun indeholdt hepatiske hændelser eller uspecificerede mavesmerter uden diagnose af pankreatitis eller øget niveau af serum lipase og/eller amylase.
A total of 40 cases were excluded from analysis as they contained only hepatic events or non-specific abdominal pain, without a diagnosis of pancreatitis or elevated serum lipase and/or amylase.
I alt blev 423 forsøgdeltagere randomiseret i forholdet 1:1 enten til kombinationen (N = 211) eller dabrafenib (N = 212).
A total of 423 subjects were randomised 1:1 to either combination (N = 211) or dabrafenib (N = 212).
I alt blev 484 patienter med målbar sygdom blev randomiseret 2:1 til enten:
A total of 484 patients with measurable disease were randomised 1:1 to either:
I alt blev 800 patienter randomiseret 2:1 til at få Lonsurf (N = 534) plus den bedste understøttende behandling (best supportive care, BSC) eller matchende placebo (N = 266) plus BSC.
In total, 800 patients were randomised 2:1 to receive Lonsurf (N = 534) plus best supportive care (BSC) or matching placebo (N = 266) plus BSC.
I alt blev 810 patienter (403 R-FC, 407 FC) i 1. linje studiet (tabel 8a og tabel 8b) og 552 patienter (276 R-FC, 276 FC) i relaps/refraktær studiet (tabel 9) analyseret for effekt.
A total of 810 patients (403 R-FC, 407 FC) for the first-line study (Table 8a and Table 8b) and 552 patients (276 R-FC, 276 FC) for the relapsed/refractory study (Table 9) were analysed for efficacy.
I alt bør De ikke få doser på mere end 5 mg/kg inden for 24 timer.
Total doses of greater than 5 mg/kg should not be administered within 24 hours.
I alt deltog 88 patienter i dette forlængelsesstudie, hvoraf 39 var behandlet med placebo, og 12 var indskrevet, men ikke randomiseret, i det tidligere studie.
In total 88 patients participated in this extension study, thereof 39 treated with placebo and 12 enrolled, but not randomised, in the previous study;
I alt deltog over 1 620 spædbørn i denne undersøgelse.
A total of 1,620 babies took part in this study.
I alt er der gennemført 14 kliniske studier med tolvaptan på verdensplan inden for ADPKD- indikationen, herunder 8 studier i USA, 1 i Holland, 3 i Japan, 1 i Korea og det multinationale, fase-3 pivotalstudie.
In total, 14 clinical trials involving tolvaptan have been completed worldwide in support of the ADPKD indication, including 8 trials in the US, 1 in the Netherlands, 3 in Japan, 1 in Korea, and the multinational phase 3 pivotal trial.
I alt er der gennemført 14 kliniske studier med tolvaptan på verdensplan inden for ADPKD-indikationen, herunder 8 studier i USA, 1 i Holland, 3 i Japan, 1 i Korea og det multinationale, fase-3 pivotalstudie.
In total, 14 clinical trials involving tolvaptan have been completed worldwide in support of the ADPKD indication, including 8 trials in the US, 1 in the Netherlands, 3 in Japan, 1 in Korea, and the multinational phase 3 pivotal trial.
I alt er der rapporteret om 119 tilfælde efter markedsføringen af bleghed og misfarvning af huden.
Cumulatively 119 post-marketing cases of pallor and skin discolouration have been reported.
I alt fik 1.774 patienter avanafil efter behov i doser på henholdsvis 50 mg (et studie), 100 mg og 200 mg (fire studier).
A total of 1774 patients received avanafil, which was taken as needed at doses of 50 mg (one study), 100 mg and 200 mg (four studies), respectively.
I alt fik 23,0 % af patienterne antiarytmika, 52,1 % betablokkere, 54,6 % ACE- hæmmere og 25,4 % statiner.
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
I alt fik 23,0 % af patienterne antiarytmika, 52,1% betablokkere, 54,6 % ACE- hæmmere og 25,4 % statiner.
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
I alt forekom lymfom/lymfoproliferative sygdomme hos 0,1 % (1/701) af patienterne i basiliximab gruppen sammenlignet med 0,3 % (2/595) af patienterne, der modtog placebo, både i kombination med to-stofs- og tre-stofs-immunsuppressiv behandling.
Overall, lymphoma/lymphoproliferative disease occurred in 0.1% (1/701) of patients in the basiliximab group compared with 0.3% (2/595) of patients receiving placebo, both in combination with dual and triple immunosuppressive therapy.
I alt fuldførte 169 patienter (47,1 %) ≥ 6 serier af vedligeholdelsesbehandlingen med pemetrexed, hvilket svarer til mindst 10 komplette serier pemetrexed.
≥ 6 cycles and a total of 103 patients (23.4 %) completed ≥ 10 cycles of treatment with pemetrexed.
I alt gennemførte 213 (48,3%) patienter ≥6 serier, og i alt 103 (23,4%) ≥10 serier med pemetrexed.
A total of 213 patients (48.3 %) completed ≥ 6 cycles and a total of 103 patients (23.4 %) completed ≥ 10 cycles of treatment with pemetrexed.
I alt har 211 voksne og pædiatriske CAPS-patienter (inklusive FCAS/FCU, MWS og NOMID/CINCA) fået Ilaris i kliniske studier.
A total of 211 adult and paediatric CAPS patients (including FCAS/FCU, MWS, and NOMID/CINCA) have received Ilaris in clinical trials.
I alt havde 22 % hiv 1-rna i plasma ved baseline på
Overall, 22% had baseline plasma HIV-1 RNA
I alt havde 54 % af patienterne en persisterende komplikation, 9 % havde samtidig bakteriæmi, og 23 % var inficeret med et levofloxacinresistent uropatogen ved baseline.
Overall, 54% of patients had a persistent complication, 9% had concurrent bacteraemia and 23% were infected with a levofloxacin resistant uropathogen at baseline.
I alt havde 660 patienter i kliniske fase 2- og fase 3-studier positive HCV-rna-resultater både ved SVR12- og SVR24-målingerne.
Overall, 660 subjects in Phase 2 and 3 clinical trials had HCV RNA results for both the SVR12 and SVR24 time points.
I alt havde mellem 95 og 100 % af børnene antistoffer mod difteri, tetanus, pertussis, hepatitis B-virus, poliovira og Hib en måned efter primærvaccinationen.
Overall, between 95 and 100% of the infants had antibodies to diphtheria, tetanus, pertussis, hepatitis B virus, polioviruses, and Hib, one month after the first vaccination course.
I alt indgik 459 patienter i studiet, hvor 152 patienter blev randomiseret til MPR+R, 153 patienter blev randomiseret til MPR+p, og 154 patienter blev randomiseret til MPp+p.
In total 459 patients were enrolled into the study, with 152 patients randomized to MPR+R, 153 patients randomized to MPR+p and 154 patients randomized to MPp+p.
I alt materiale skal der henvises til produktresumeét for fyldestgørende produktinformation.
All materials will refer to summary of product characteristics for full prescribing information.
I alt N = 111
Total N = 111
i alt n = 55
Total subjects4 N=55
I alt oplevede 32,2 % af patienterne bivirkninger.
Overall 32.2% of the patients experienced adverse drug reactions.
I alt randomiseredes 1.106 patienter, 553 til hver arm.
A total of 1,106 patients were randomised, 553 to each arm.
I alt randomiseredes 1.106 patienter, 553 til hver arm.
A total of 1.106 patients were randomised, 553 to each arm.
I alt randomiseredes 2.866 patienter, og 2.856 patienter blev behandlet.
A total of 2,866 patients were randomized and 2,856 patients were treated.
I alt var 50,0 % af patienterne kvinder.
A total of 50.0% of patients were female.
I alt var 54 % af patienterne kvinder.
A total of 54% of patients were female.
I alt var 74 % af de inkluderede kvinder naive over for både HPV-16 og HPV-18 (dvs.
Overall, 74% of women enrolled were naïve to both HPV-16 and HPV-18 (i.e.
I alt var der vedvarende respons hos 42 % af de patienter (36 ud af 85), der fik Krystex- xa hver anden uge, og hos 35 % (29 ud af 84) af dem, der fik Krystexxa hver fjerde uge.
Overall, 42% of patients (36 out of 85) given the medicine every two weeks showed a persistent response; the figure for those given Krystexxa every four weeks was 35% (29 out of 84).
I alvorlige tilfælde kan disse reaktioner indvirke på nogle daglige aktiviteter, og de kan vare i 4 uger eller længere før komplet helbredelse.
In severe cases, these effects may interfere with certain daily activities, and may last for 4 weeks or longer before resolving completely.
I AMPLIFY-studiet blev ialt 5.395 patienter randomiseret til behandling med apixaban 10 mg oralt to gange dagligt i 7 dage efterfulgt af apixaban 5 mg oralt to gange dagligt i 6 måneder eller til enoxaparin 1 mg/kg subkutant to gange dagligt i mindst 5 dage (indtil INR 2) og warfarin (målinterval for INR 2,0-3,0) oralt i 6 måneder.
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
I AMPLIFY-studiet blev ialt 5.395 patienter randomiseret til behandling med apixaban 10 mg oralt to gange dagligt i 7 dage efterfulgt af apixaban 5 mg oralt to gange dagligt i 6 måneder, eller til enoxaparin 1 mg/kg subkutant to gange dagligt i mindst 5 dage (indtil INR 2) og warfarin (målinterval for INR 2,0-3,0) oralt i 6 måneder.
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
I analysen af et supplerende studie, Studie C211, svarede sikkerhedsprofilen af kombinations- behandling med INCIVO 1.125 mg to gange dagligt til sikkerhedsprofilen hos patienter, der fik kombinationsbehandling med INCIVO 750 mg hver 8. time.
In the analysis of an additional study, Study C211, the safety profile of combination therapy with INCIVO 1,125 mg twice daily was similar to the safety profile for patients receiving combination therapy with INCIVO 750 mg every 8 hours.
I analysen af responsraten (non-completer lig med failure analysen [NC = F]), blev patienter, der udgik af studiet tidligt uanset grund, patienter som manglede en hiv- RNA måling, som enten var forudgået eller blev efterfulgt af en måling over assaygrænsen, formodet at have hiv-RNA over 50 eller over 400 kopier/ml på de manglende tidspunkter.
In the analysis of responder rates (the non-completer equals failure analysis [NC = F]), patients who terminated the study early for any reason, or who had a missing HIV-RNA measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have HIV-RNA above 50 or above 400 copies/ml at the missing time points.
I analysen af responsraten (non-completer lig med failure analysen[NC = F]), blev patienter, der udgik af studiet tidligt uanset grund, patienter som manglede en hiv-RNA måling som enten var forudgået eller blev efterfulgt af en måling over assaygrænsen, formodet at have hiv-RNA over 50 eller over 400 kopier/ml på de manglende tidspunkter.
In the analysis of responder rates (the non-completer equals failure analysis [NC = F]), patients who terminated the study early for any reason, or who had a missing HIV-RNA measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have HIV-RNA above 50 or above 400 copies/ml at the missing time points.
I analysen af uge 48 til uge 96 forekom der yderligere 24 (3,5 %) og 14 (2,1 %) tilfælde af virologisk svigt i henholdsvis rilpivirin- og efavirenz- gruppen.
From the week 48 to the week 96 analysis, 24 (3.5%) and 14 (2.1%) additional virologic failures occurred in the rilpivirine and efavirenz arm, respectively.
I analysen er medtaget bivirkninger fra første indtagelse af dabigatranetexilat eller warfarin efter ophør af parenterel behandling (kun oral behandlingsperiode).
Adverse drug reactions for both treatments, dabigatran etexilate and warfarin, are counted from the first intake of dabigatran etexilate or warfarin after the parenteral therapy has been discontinued (oral only treatment period).
I analysen ved slutningen af studiet reducerede Cervarix antallet af definitive cervikale behandlingsprocedurer (inkluderende Loop-Electro-Excision Procedure (LEEP), koldknivskonisering og laserbehandling) med 70,2 % (95 % CI: 57,8; 79,3) i kohorten TVC-naive og med 33,2 % (95 %
At the end of study analysis, Cervarix reduced definitive cervical therapy procedures (includes loop electrosurgical excision procedure [LEEP], cold-knife Cone, and laser procedures) by 70.2% (95% CI: 57.8;79.3) in TVC-naïve and 33.2% (95% CI: 20.8;43.7) in TVC.
I anden del blev patienter med klinisk respons på dag 90 randomiseret til at fortsætte med Enbrel eller få placebo i fire måneder for at evaluere, om sygdommen blussede op.
In part 2, patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for four months and assessed for disease flare.
I anden del blev patienterne med klinisk respons på dag 90 randomiseret til at forsætte med Enbrel eller få placebo i fire måneder for at evaluere, om sygdommen blussede op.
In part 2, patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for four months and assessed for disease flare.
I anden del fik 6 af 25 (24 %) patienter, som fortsatte med Enbrel, sygdomsopblussen sammenlignet med 20 af
In part 2, 6 of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of
I andet og tredje trimester af graviditeten var middelværdierne for disse parametre sammenlignelige.
During the 2nd and 3rd trimester of pregnancy mean values of these parameters were comparable.
I andre studier (prospektive og tværgående) sås de mest udtalte fald i BMD hos patienter, som fik tenofovirdisoproxilfumarat som del af et regime, der indeholdt en boostet proteasehæmmer.
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil fumarate as part of a regimen containing a boosted protease inhibitor.
I andre studier (prospektive studier og tværsnitsstudier) sås de mest udtalte reduktioner i BMD hos patienter, der blev behandlet med tenofovirdisoproxilfumarat som del af et regime indeholdende en boostet proteasehæmmer.
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil fumarate as part of a regimen containing a boosted protease inhibitor.
I andre studier med somatropin vedr. generel toksicitet, lokal tolerance og reproduktionstoksicitet er der ikke observeret klinisk relevante effekter.
In other studies with somatropin regarding general toxicity, local tolerance and reproduction toxicity no clinically relevant effects have been observed.
I andre tilfælde anbefales det at give flere leukafereser.
In other circumstances, additional leukaphereses are recommended.
I andre tilfælde skal der søges hjælp hurtigtst muligt.
In other cases, seek help as soon as possible
I andre tilfælde vil din læge eventuelt først stoppe din ægløsning ved hjælp af et gonadotropin- frigivende hormon (GnRH)-agonist eller -antagonist.
In other cases, your doctor may first stop you from ovulating by using a gonadotropin-releasing hormone (GnRH) agonist or antagonist.
I ankyloserende spondylitis-studie 1 (AS-studie 1) og ankyloserende spondylitis-studie 2 (AS-studie 2) var henholdsvis 27,0 % og 38,8 % af patienterne tidligere blevet behandlet med et anti-TNF-middel, og anti-TNF-midlet var blevet seponeret enten pga. manglende effekt eller intolerans (anti-TNF-IR- patienter).
In Ankylosing Spondylitis Study 1 (AS Study 1) and Ankylosing Spondylitis Study 2 (AS Study 2) 27.0% and 38.8% of patients, respectively, were previously treated with an anti-TNFα agent and discontinued the anti-TNFα agent for either lack of efficacy or intolerance (anti-TNFα-IR patients).
I APC-forsøget ses en dosisrelateret stigning i det sammensatte endepunkt af kardiovaskulær død, myokardieinfarkt eller slagtilfælde (bekræftet) med celecoxib sammenlignet med placebo over en behandlingsperiode på 3 år.
In theAPC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment.
I apixaban- versus warfarinstudiet var incidensen af ISTH major gastrointestinal blødning (inklusive øvre gastrointestinal, nedre gastrointestinal og rektal blødning) 0,76%/år med apixaban.
In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year.
i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
By reporting side effects you can help provide more information on the safety of this medicine.
i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
I arm-B bestod det anvendte XELIRI-regime af 1.000 mg/m2 capecitabin 2 gange dagligt i 14 dage plus 250 mg/m2 irinotecan på dag 1.
For Arm B, the XELIRI regimen used capecitabine 1000 mg/m2 twice daily for 14 days +irinotecan 250 mg/m2 on day
I armen med efavirenz+emtricitabin/ tenofovirdisoproxilfumarat var den gennemsnitlige ændring i total kolesterol (fastende) 26 mg/dl, i
In the efavirenz+emtricitabine/tenofovir disoproxil fumarate arm the mean change from baseline in total cholesterol (fasted) was 26 mg/dL, in
I armen med fast ugentligt interval fik forsøgspersonerne ALPROLIX som rutinemæssig profylakse, startende med 50 IU/kg.
In the fixed weekly interval arm, subjects received ALPROLIX for routine prophylaxis starting at 50 IU/kg.
I armen med individualiseret profylakse startede forsøgspersonerne med behandling to gange ugentligt med 25 IU/kg på den første dag, efterfulgt af 50 IU/kg på fjerde dagen.
In the individualised prophylaxis arm, subjects started with a twice weekly regimen consisting of 25 IU/kg on the first day followed by 50 IU/kg on the fourth day.
I armen med individuelle intervaller fik forsøgspersonerne ALPROLIX som rutinemæssig profylakse med en fast dosis på 100 IU/kg med et doseringsinterval startende hver 10. dag.
In the individualised interval arm, subjects received ALPROLIX for routine prophylaxis at a fixed dose of 100 IU/kg in a dosing interval starting at every 10 days.
I ARROW-studiet (COL105677) blev 1.206 pædiatriske patienter i alderen fra 3 måneder til 17 år doseret i henhold til deres vægt, på basis af dosisanbefalingerne fra WHO’s behandlingsguidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
I ART resulterede det i, at follitropin alfa ved en lavere total dosis og en kortere behandlingsperiode opnåede et højere antal af udtagne oocytter sammenlignet med u-FSH.
In ART, follitropin alfa at a lower total dose and shorter treatment period than urinary FSH, resulted in a higher number of oocytes retrieved when compared to urinary FSH.
I artiklen af Besouw et al (2011) bragte forfatterne beskrivelser af 6 mandlige pædiatriske patienter (alder ved sygdommens opståen fra 3 til 15 år) med cystinose, som oplevede bivirkninger under behandlingen med cysteamin.
In the paper by Besouw et al (2011), the authors provided description of 6 male paediatric patients (age at onset ranged 3-15 years) with cystinosis who experienced adverse effects while receiving cysteamine.